Investor Presentaiton

Made public by

sourced by PitchSend

1 of 33

Creator

PitchSend logo
PitchSend

Category

Pending

Published

Unknown

Slides

Transcriptions

#1C NH www.polymedicure.com POLYMED MEDICAL DEVICES We Care As We Cure Jishash Investors Presentation NH HS OH HN May 2023 Confidential | Slide 1#2POLYMED MEDICAL DEVICES We Care As We Cure DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the "Company") solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By accessing this presentation, you agree to be bound by the following restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any persons of such change or changes. This presentation and its contents are confidential and may not be copied, published, reproduced or disseminated in any manner. This presentation may contain certain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company which are expressed in good faith and in their opinion, reasonable. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition of the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward-looking statements as a result of various factors and assumptions which the Company believes to be reasonable in light of its operating experience in recent years. Many factors could cause the actual results, performances, or achievements of the Company to be materially different from any future results, performances, or achievements. Significant factors that could make a difference to the Company's operations include, but are not reasonable to, domestic and international economic conditions, changes in government regulations, tax regime and other statutes. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. This presentation contains certain supplemental measures of performance and liquidity that are not required by or presented in accordance with Indian GAAP, and should not be considered an alternative to profit, operating revenue or any other performance measures derived in accordance with Indian GAAP or an alternative to cash flow from operations as a measure of liquidity of the Company. In no event shall the Company be responsible to any person or entity for any loss or damage, whether direct, indirect, incidental, consequential or otherwise, arising out of access or use or dissemination of information contained in this presentation, including, but not limited to, loss of profits. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Company, its advisors and representative and any of its or their affiliates, officers, directors, employees or agents, and anyone acting on behalf of such persons accepts any responsibility or liability whatsoever, in negligence or otherwise, arising directly or indirectly from this presentation or its contents or otherwise arising in connection therewith. You must make your own assessment of the relevance, accuracy and adequacy of the information contained in this presentation and must make such independent analysis as you may consider necessary or appropriate for such purpose. Any opinions expressed in this presentation are subject to change without notice and past performance is not indicative of future results. By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This presentation and its contents are not and should not be construed as a prospectus or an offer document, including as defined under the Companies Act, 2013, to the extent notified and in force) or an offer document under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended. This presentation is not for publication or distribution or release in any country where such distribution may lead to a breach of any law or regulatory requirement. The information contained herein does not constitute or form part of an offer, or solicitation of an offer to purchase or subscribe, for securities for sale. The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration therefrom. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Delhi, and no other courts, shall have jurisdiction over the same. www.polymedicure.com Confidential | Slide 2#3Table of Contents Polymed at a Glance 4 Board of Directors 9 Manufacturing Excellence 11 Research and Development 15 Sustainability Reporting 17 Financial Data 19 Medical Devices Policy 2023 23 Way Forward 26 Capex Update 27 Awards and Corporate Communication 28 www.polymedicure.com POLYMED MEDICAL We Care As We Cure DEVICES Confidential | Slide 3#4Polymed at a Glance Toil ជំនួ POLYMED MEDICAL DEVICES We Care As We Cure OB O 300+ Sales Associates О 125+ INR 1115 Crores 0 30+ 160+ Countries Consolidated Revenue Clinical Specialists Medical Devices www.polymedicure.com Largest Exporter of consumable Medical devices, 9 yrs in a row 3000+ Employee Base 1 Billion+ Devices Manufacturing Capacity per year Confidential | Slide#5Polymed's Unique Position EMINENCE IN FLUID MANAGEMENT DISPOSABLES AND PROCEDURAL MEDICAL DEVICES COMPREHENSIVE PRODUCT RANGE Oncology Gastroentrology Urology Renal Care & Dialysis Surgery and Wound Drainage Infusion & Vascular Access Molecular Diagnostics Critical Care Anaesthesia & Respiratory Care Blood Management & Blood Collection Systems POLYMED MEDICAL DEVICES We Care As We Cure Portfolio of more than 160+ Medical Devices www.polymedicure.com 26 Years of manufacturing excellence Confidential | Slide 6#6Our Journey.......... A SUCCESSFUL STORY SPANNING OVER 25 YEARS 1997 Commencement of Manufacturing Operation 2001 Expansion of Faridabad Plant 2002 JV in Egypt 2004 2007 2009 Faridabad Plant-2 Extension (100% New Plant Haridwar China Plant EOU) 2014 New Plant at SEZ Jaipur 2016 New R&D Center POLYMED MEDICAL DEVICES We Care As We Cure 2011 Company Listed in NSE *2023 Faridabad, Sector 59, *2023 SEZ Jaipur Expansion Phase III *2023 IMT Faridabad Plant Expansion 2018 2020 2021 New Plant at IMT Faridabad IMT Faridabad expansion Phase II Acquired Plan1Health, PolyHealth Medical Inc. USA Subsidiary of Poly Medicure Ltd 2 New Plants Expansion Italy www.polymedicure.com *Work in progress Established in 1997, POLYMED is a key player in the Indian Medical Devices Industry Confidential | Slide 6#7Corporate Structure www.polymedicure.com INDIA POLYMED GROUP OVERSEAS Poly Medicure Ltd Holding Co. Poly Medicure (Laiyang) Co. Ltd. China Wholly owned Subsidiary (100%) Poly Medicure BV- Netherlands Wholly owned Subsidiary (100%) Ultra for Medical Products Co. (UMIC) - Egypt Associate (23%) Plan 1 Health India Pvt. Ltd. Wholly owned Subsidiary (100%) Plan 1 Health Italy Step Down Subsidiary (100%) PolyHealth Medical Inc. USA Step Down Subsidiary (100%) POLYMED MEDICAL DEVICES We Care As We Cure Confidential | Slide 7#82020-2025 Vision TRANSFORM FROM A PRODUCT COMPANY TO A SOLUTION PROVIDER ORGANIZATION Started in 1997 2002-2009 2011-2019 Commencement of Product and facility New R&D Center Manufacturing Operation expansion Acq of Plan 1 Health New Manufacturing Plants Value Based Supplier TODAY Preferred Supplier Supplier of 1st Choice Solutions Partner Driving Delivery of Health Care • 2020-2021 Focus on commercial launch of current product pipeline Invest in development of infection reduction and fluid management and accelerate time to market Upscale R&D and Operations 2022-2025 Launch differentiated new products in premium markets and geographies Accelerate growth in developed countries Develop critical care range of products POLYMED MEDICAL DEVICES We Care As We Cure 2026 and beyond Globally recognized solution provider of infection reduction technologies and fluid management products www.polymedicure.com Confidential | Slide 8#9Board of Directors & Management Mr. Devendra Raj Mehta (Chairman, Non-Executive Independent Director) Mr. Himanshu Baid (Managing Director) POLYMED MEDICAL DEVICES We Care As We Cure Mr. Rishi Baid (Joint Managing Director) Mr. Jugal Kishore Baid (Non-Executive Director) Mrs. Mukulika Baid (Non-Executive Director) Dr. Shailendra Raj Mehta (Non-Executive Independent Director) Mr. Prakash Chand Surana (Non-Executive Independent Director) Mr. Amit Khosla (Non-Executive Independent Director) www.polymedicure.com ETHE Mr. Alessandro Balboni (Non-Executive Non-Independent Director) Dr. Sandeep Bhargava (Non-Executive Independent Director) Ms. Sonal Mattoo (Non-Executive Independent Director) Dr. Ambrish Mithal (Non-Executive Independent Director) Confidential | Slide 9#10Executive Global Leadership Building out Geographical Leadership with strong medical device experience & expertise WoCo POLYMED MEDICAL DEVICES We Care As We Cure Heyward Powe VP Sales & Business Development, North & Central America 24 years Medical Device Experience He brings a wealth of knowledge with Hospital Sales, Group Purchasing Organizations, Global and Regional Distribution, Integrated Delivery Networks, and Value Analysis Committees. www.polymedicure.com Alessando Balboni Managing Director EMEA and CEO Plan1Health, Board Member • . • 26 years Medical Device Experience Previous CEO Delta Med Spa, Paul Hartmann SPA MBA from Università di Bologna WOCO Xue Wendong Prof. Sergio Bertoglio Chief Medical Officer • Professor of Surgery at the Department of Surgical Sciences of the Faculty of Medicine, University of Genova, Italy Staff surgeon at the 1st General Surgery Unit of the Policlinico San Martino Genova, Italy General Manager, China 20 years Medical Device Experience Managing Polymed China Facility Confidential | Slide 10#11Across the World, We serve people in over 125+ countries Our Growth Verticals Vascular Access Dialysis & Renal Care Transfusion System Dignostics Oncology www.polymedicure.com Plan Health POLYMED MEDICAL DEVICES POLYMED MEDICAL DEVICES We Care As We Cure POLYMED HQ ▲ MANUFACTURING UNITS ■PLAN1HEALTH NEW PLANTS 4 new Plants under Construction UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS Confidential | Slide 11#12POLYMED POLYMED MEDICAL DEVICES We Care As We Cure Faridabad Plant, India Haridwar Plant, India IMT Faridabad India Manufacturing (INDIA, ITALY, EGYPT, CHINA) = II 1st Medical Device Company from India to have overseas plants. Over 300+ Moulding Machines & 1200+ Injection Molds More than 200+ automatic assembly machines with vision control systems. 50+ Robots used in manufacturing. POLYMED www.polymedicure.com POLYMED POLYMED Faridabad Plant, India Jaipur Plant, India R & D Center, FBD, India OLYMED 宝利脉(茉阳)医疗用品有限公司 POLY MEDICURE CLATVANGS CO. LTD Laiyang-qingdao, China Plan Health Assuit, Egypt Amaro, Italy Confidential | Slide 12#13www.polymedicure.com Manufacturing Excellence SUR EXIT POLYMED MEDICAL DEVICES We Care As We Cure Confidential | Slide 13#14Manufacturing Excellence www.polymedicure.com ≡≡ Di DO NOT TOUCH DO NOT TOUCH EMP 20 POLYMED MEDICAL DEVICES We Care As We Cure Confidential | Slide 14#15• • Research and Development Capabilities Product Design & Development Product Design using CAD Software ProE Creo, Solidworks, NX, AutoCAD 1 Dedicated R&D Quality Lab for Design Verification Program Management skills 3D Printing Prototype facility PLC Programming Patents Granted (as on 31.03.2023) www.polymedicure.com 372 71 FA POLYMED MEDICAL DEVICES We Care As We Cure Tooling Mold Design & Development Mold Flow Analysis for simulation VMC, CNC machines EDM/Wirecut/Milling/ Centerless Grinder Laser Welding & Etching 2 • Pending Patent Applications (as on 31.03.2023) Confidential | Slide 15#16Research and Development Capabilities Manufacturing Process . • Cannula manufacturing Ultrasonic Welding Radio Frequency Welding Thermal Bonding Hot Air Welding Laser Welding Plasma Welding UV Gluing & Curing Hydrophilic Coating Micro-drilling-Eyelet cut/punch (SS/Plastic) Pad printing FORM 20 R&D Laser printing www.polymedicure.com POLYMED MEDICAL DEVICES We Care As We Cure • Processing capabilities Injection Molding Horizontal M/C's Insert Molding (Vertical M/C's) • Extrusion (PVC, PU, FEP) Blow Molding Sheet Extrusion Confidential | Slide 16#17ZERTIFIKAT CERTIFICATE E CЕРТИ И кАT CERTIFICADO CERTIFICAT Sustainability & MDSAP Certifications CERTIFICATE The Certification Body of TÜV SÜD South Asia Private Limited certifies that TUV South Asia POLYMED REDITAL DEVICES Poly Medicure Limited Plot No. PA 010-018, PA 010-019, Mahindra world city (Jaipur) Ltd., Multi product SEZ Jaipur - 302 037, Rajasthan, India has implemented Environmental Management System in accordance with ISO 14001:2015 for the scope of Manufacture, Warehouse, Sales and Marketing of Sterile / Non-Sterile Medical Devices for Infusion, Transfusion, General Surgery, Anaesthesia, Gastroenterology, Respiratory, Diagnostics and Cardiogram by Injection Moulding, Plastic Extrusion, Assembly, Packing and Sterilization The certificate is valid from 2022-06-29 until 2025-06-28 Subject to successful completion of annual periodic audits The present status of this certificate can be obtained through TUV SUD website by scanning below QR code and by entering the certificate number (without spaces) on web page. Further clarifications regarding the status & scope of this certificate may be obtained by consulting the certification body at [email protected] Certificate Registration No. 99 104 01414 Date of Initial certification: 2022-06-29 Issue Date: 2022-06-29 Rev. 00 Breake Rahul Kale Head of Certification Body of TÜV SÜD South Asia Private Limited, Mumbai TUV SUD IAF Member of TÜV SÜD Group NABCB EM009 TÜV SÜD South Asia Pvt. Ltd. ⚫ TÜV SÜD House Saki Naka Andheri (East) Mumbai-400072 Maharashtra India www.polymedicure.com TUV ZERTIFIKAT CERTIFICATE E ECEPTиикАт сERTIFICADO CERTIFICAT ISO-14001 CERTIFICATE The Certification Body of TÜV SÜD South Asia Private Limited certifies that POLYMED MEDICAL DEVICES Poly Medicure Limited TUV South As Plot No-34, Sector-68, IMT, Faridabad - 121 004, Haryana, India has implemented Environmental Management System in accordance with ISO 14001:2015 for the scope of Design & Development, Manufacture, Sales and Distribution of Sterile & Non-Sterile Non-Active Non-Implantable Medical Devices for Infusion, Transfusion, General Surgery, Dialysis, Urology, Anaesthesia, Gastroenterology, Cardiovascular, Invitro Diagnostic Respiratory by Injection Moulding, Plastic Extrusion, Assembly, packing and sterilization. The certificate is valid from 2022-06-29 until 2025-06-28 Subject to successful completion of annual periodic audits The present status of this certificate can be obtained through TUV SUD website by scanning below QR code and by entering the certificate number (without spaces) on web page. Further clarifications regarding the status & scope of this certificate may be obtained by consulting the certification body at [email protected] Certificate Registration No. 99 104 01415 Date of Initial certification: 2022-06-29 Issue Date: 2022-06-29 Rev. 00 Reveale Rahul Kale Head of Certification Body of TÜV SÜD South Asia Private Limited, Mumbai Member of TÜV SÜD Group TUV IAF NABCB EM009 ZERTIFIKAT CERTIFICATE СЕРТиикАT CERTIFICADO CERTIFICAT MDSAP MEDICAL DEVICE SINGLE AUDIT PROGRAM CERTIFICATE No. QS6 105485 0009 Rev. 00 Certificate Holder: Certification Mark: Scope of Certificate: Standard(s): Regulatory Authority(ies): POLY MEDICURE LIMITED Plot No. 34 Sector-68, IMT Faridabad, Haryana 121004 INDIA Q TÜV SUD TUV SUD America Manufacture of IV Catheters (Cannula) with/without Safety Features, Infusion Sets, Prefilled Syringe with Saline Solutions, Vial Access Spike, Needle Free Connectors, Auto Disable Syringes, Safety Huber Needle, Spinal Needle, Endotracheal Tubes, Disinfecting Port Protectors, Fistula Needle with/without Safety Features, Blood Line Sets, Dialysis Filters for the areas of Infusion, Anesthesia and Dialysis ISO 13485:2016 Brazil ANVISA, Health Canada, USA FDA. See attached for listing of specific regulatory requirements. The Certification Body of TÜV SÜD America Inc. certifies that the quality management system of the manufacturer listed above has been audited against the stated criteria and found to conform to those criteria for the scope of certification listed. Validity of this certificate can be obtained by visiting the website www.tuvsud.com/ps-cert TÜV SÜD America Inc. is an MDSAP Recognized Auditing Organization. REPS Facility ID: Effective Date: Expiry Date: Page 1 of 2 Date of Issue: 2022-06-28 F005858 2022-06-16 2025-06-15 жи (Renee Walker) Manager, US Certification Body. Medical and Health Services TÜV SÜD America, Inc. 401 Edgewater Place Suite #500 - Wakefield MA 01880 - USA - www.tuvsud.com TUV TÜV SÜD South Asia Pvt Ltd. ⚫TÜV SÜD House Saki Naka ⚫Andheri (East) Mumbai-400072 Maharashtra India TUV ZERTIFIKAT CERTIFICATE ♦ ♦сЕРТИикAT CERTIFICADO CERTIFICAT MDSAP MDSAP MEDICAL DEVICE SINGLE AUDIT PROGRAM POLYMED MEDICAL DEVICES We Care As We Cure CERTIFICATE No. QS6 105735 0007 Rev. 00 Certificate Holder: Poly Medicure Limited Certification Mark: Plot No.PA-010-018, PA-010-019 Mahindra World City (Jaipur) Ltd, Multi-Product SEZ Jaipur, Rajasthan 302037 INDIA TÜV SUD Scope of Certificate: Standard(s): Regulatory Authority(ies): Manufacture of IV Catheters (Cannula) with/without Safety Features, Infusion Sets, Safety Hypodermic Needles, Safety Winged Infusion Set, Blood Transfusion Set, Blood Collection Needle with/without Safety Feature, Blood Collection Tubes, Suction Catheters, Infant Feeding Tubes, High Pressure Vacuum Drainage Bottle, Yankaur Suction Set (Suction Tube and / or Handle), ECG Electrodes and Alcohol Swabs for the areas of Infusion, Transfusion, Diagnostics, Anesthesia, Gastroenterology, General Surgery, Heartbeat Monitoring and Disinfecting ISO 13485:2016 Brazil ANVISA, Health Canada, USA FDA. See attached for listing of specific regulatory requirements. The Certification Body of TÜV SÜD America Inc. certifies that the quality management system of the manufacturer listed above has been audited against the stated criteria and found to conform those criteria for the scope of certification listed. Validity of this certificate can be obtained by visiting the website www.tuvsud.com/ps-cert TÜV SÜD America Inc. is an MDSAP Recognized Auditing Organization. REPS Facility ID: Effective Date: Expiry Date: F005860 2022-07-26 2025-07-25 Page 1 of 2 Date of Issue: 2022-08-09 (Renee Walker) Manager, US Certification Body, Medical and Health Services TÜV SÜD America, Inc. 401 Edgewater Place Suite #500 ⚫ Wakefield MA 01880 USA⚫www.tuvsud.com TUV Confidential | Slide 18 TUV SUD America#18Stickiness in customer base & sustainable business LEVERAGE OUR (CUSTOMER) INSTALLED BASE AND DISTRIBUTOR NETWORK TO LAUNCH NEW PRODUCTS POLYMED MEDICAL DEVICES We Care As We Cure Polymed Sales By Geography Polymed Sales By Product Category Polymed Brand and OEM Private Label Sales 32% www.polymedicure.com 3% 4% 10% 68% 9% 7% 67% 30% Export India Infusion Therapy Blood Transfusion Surgery & Wound Drainage Anaesthesia & Respiratory Renal PolyMed Brand OEM Other 70% Confidential | Slide 17#191200.00 Our Strength: Consistent all-round growth (Consolidated) ☑ REVENUE (Crs) POLYMED MEDICAL DEVICES We Care As We Cure EBIDTA (Crs) PBT (Crs) PAT (Crs) 1115.23 923.06 300.00 269.38 250.00 237.49 200.00 179.28 1000.00 195.24 786.20 250.00 214.34 213.10 200.00 180.04 146.51 800.00 150.00 135.841 200.00 150.00 600.00 150.00 100.00 400.00 100.00 100.00 50.00 200.00 50.00 50.00 0.00 0.00 0.00 0.00 PAT FY 2022 ■FY 2023 Revenue EBIDTA PBT ■FY 2021 FY 2022 FY 2023 FY 2021 FY 2022 ■FY 2023 FY 2021 FY 2022 FY 2023 FY 2021 Year Revenue CAGR FY 2021 786.20 Year FY 2021 EBIDTA % 214.34 27.26% Year FY 2021 PBT % 180.04 FY 2022 923.06 20% FY 2022 213.10 23.09% FY 2022 195.24 22.90% 21.15% Year FY 2021 PAT FY 2022 FY 2023 1115.23 FY 2023 269.38 24.16% FY 2023 237.49 21.30% FY 2023 www.polymedicure.com % 135.84 17.28% 146.51 15.87% 179.28 16.08% Confidential | Slide 19#20Creating Value for Shareholders 40000 35000 Increasing Shareholders Base 30000 25000 20000 15000 8574 10000 5000 0 31-03-2020 www.polymedicure.com NO. OF SHAREHOLDERS 21531 POLYMED MEDICAL DEVICES We Care As We Cure Creating Value for Shareholders MARKET CAP IN INR (CRS) 10000 35393 33831 9000 8000 7000 6000 5000 4000 3000 2056.36 2000 1000 0 No of Shareholders 31-03-2021 31-03-2022 31-03-2023 Date No of Shareholders 31-03-2020 8,574 31-03-2021 21,531 31-03-2022 33,831 31-03-2023 35,393 31-03-2020 7884.74 9105.74 Market Cap 31-03-2021 31-03-2022 9140.14 31-03-2023 Date Market Cap in INR (Crs) 31-03-2020 2056.36 31-03-2021 7884.74 31-03-2022 9105.74 31-03-2023 9140.14 Confidential | Slide 20#21Ratio's 70 60 Interest Coverage 50 40 29.58 30 20 14.32 10 0 64.53 Debt Service Coverage 12 10 41.34 8 6.87 5.55 6 4.61 4 % FY 2020 FY 2021 FY 2022 FY 2023 20 9.91 % ■FY 2020 FY 2021 FY 2022 FY 2023 ROCE 30.00% 21.03% 20.00% 15.49% 16.47% 14.05% 10.00% 0.00% * Increase in Share Capital due to QIP in Feb 2021 www.polymedicure.com * % FY 2020 FY 2021 FY 2022 ■FY 2023 POLYMED MEDICAL DEVICES We Care As We Cure Confidential | Slide 21#221200.00 1000.00 800.00 600.00 400.00 200.00 0.00 Revenue www.polymedicure.com Performance Standalone/Consolidated 747.38 879.36 1068.05 208.30 212.13 268.48 FY 2021 EBIDTA Standalone in INR Crs 173.36 194.72 236.88 PBT FY 2022 FY 2023 129.50 146.02 179.04 PAT Poly Medicure Ltd 1200.00 1000.00 800.00 600.00 400.00 200.00 786.20 923.06 1115.23 214.34 213.10 269.38 Consolidated in INR Crs 180.04 195.24 0.00 Revenue EBIDTA PBT ■FY 2021 FY 2022 ■FY 2023 237.49 135.84 146.51 179.29 PAT Confidential | Slide 22 POLYMED MEDICAL DEVICES We Care As We Cure#23New National Medical Devices Policy 2023 POLYMED MEDICAL DEVICES We Care As We Cure MEDICAL VEDICAL 0 CABINET GIVES NOD TO MEDICAL DEVICES POLICY 2023 Vision: ✓ Accelerated growth path with a patient-centric approach ✓ To emerge as the global leader in the manufacturing and innovation of medical devices by achieving 10-12% share in the expanding global market over the next 25 years. ✓ Policy is expected to help the Medical Devices Sector grow from present $11 Bn to $50 Bn by 2030. Mission: Policy lays down a roadmap for accelerated growth of the medical devices sector to achieve the following missions viz, ✓ Access & Universality ✓ Affordability, ✓ Quality, ✓ Patient Centred & Quality Care, ✓ Preventive & Promotive Health Security, ✓ Research and Innovation and Skilled manpower. www.polymedicure.com Confidential | Slide 23#24New National Medical Devices Policy 2023 POLYMED MEDICAL DEVICES We Care As We Cure Strategies to Promote Medical Device Sector: • • Regulatory Streamlining: creation of a Single Window Clearance System, enhancing the Role of BIS and designing a coherent pricing regulation. Enabling Infrastructure: The establishment and strengthening of large medical device parks. Facilitating R&D and Innovation: Department's proposed National Policy on R&D and Innovation in the Pharma- MedTech Sector. Attracting Investments in the Sector: encourages private investments, Venture Capitalists, and also Public-Private Partnership(PPP). Human Resources Development: to have a steady supply of skilled work force across the value chain Brand Positioning and Awareness Creation: Dedicated Export Promotion Council enabling market access. www.polymedicure.com Confidential | Slide 24#25POLYMED MEDICAL DEVICES We Care As We Cure Production Linked Incentive Scheme (I & II) Pharmaceutical and medical device industry reacts positively for Government PLI Scheme • • Polymed got approval under Renal Care Segment. New Cardio range to be added Committed Investment of 70 Crs under the scheme from FY 2022-28 25.5 Crs of Investment done upto Mar-23 under the scheme www.polymedicure.com Related Articles Apparatus Related Reagents Calibrators In Vitro Diagnostics Related Instruments Software Materials Control Specimen Receptacles • • . Polymed got approval under In Vitro Diagnostic Medical devices. New range of Molecular Chemicals, reagents and diagnostic kits added. Committed Investment of 50 Crs under the scheme from FY 2021-28 • 22 Crs of Investment done upto Mar-23 under the scheme. Qualified to claim incentive for 2022-23 Confidential | Slide 25#26• Way Forward ... Vascular Access Be a leading global player Expand footprint in Europe & USA • Renal Introduce Indigenous Dialysis Machine • Expand Dialyzer range Research & Development Increase R&D investments Shorter lead time for commercialization www.polymedicure.com 01 02 12 03 83 04 POLYMED MEDICAL DEVICES We Care As We Cure International Strategy Transition to MDR Improve Brand visibility in International markets Received US FDA 510(K) clearance for two products 55 05 Promote Infection Prevention and Safety Targeted Clinical engagement 06 90 Operational Excellence Build sustainability Adopt best ESG standards ISO 14001 Confidential | Slide 26#27• Capex Update Capex incurred in FY 2022-23: INR 237 Crs • Capex planned for FY 2023-24 INR 200 Crs Premises under Construction as on 31st March 2023 Jaipur SEZ Phase - II Scheduled Operation Q1 -2023-24 www.polymedicure.com POLYMED MEDICAL DEVICES We Care As We Cure Faridabad Manufacturing and Warehouse 56A Scheduled Operation Q1 -2023-24 Faridabad Plant 117 Scheduled Operation Q2 -2023-24 Faridabad IMT Plant II Scheduled Operation Q3 -2023-24 Confidential | Slide 27#28Awards & Recognition www.polymedicure.com CH INNOVATION CII Industrial Innovation Awards 2022 This is to certify that Poly Medicure Limited is cer of the Top 50 Innovative Companies December 2022 Bassan CH CR INDUSTRIAL INNOVATION AWARDS 2027 TOP 50 INNOVATIVE COMPANY POLY MEDICURE LIMITED "Top 50 Innovative Companies Award 2022" By Confederation of Indian Industry - Received in December 2022 POLYMED MEDICAL DEVICES We Care As We Cure Confidential | Slide 28#29Corporate Communication Media | Industry Events I Webinars | Social Media I Clinical Engagements I Conferences P+LYMED BIRTH DEFECTS f in Healthy Mothers birth Strong Babies Ensure a healthy pregnancy to ensur a mopy future for your child 1 lac + followers on social media, 250 posts pushed last year FORTUNE INDIA THE NEXT 500 After a tough year. The Next500 comparies cumulatively got back into the black. How did the best performers handle an unexpected crisis? FICCI PLYMED FICCI PHUMED FICCI PLMED P+MED FICCI PHYMED FICCI P+D/MED FICCI VED FICCI PHMED FICCI P+LYMED INDIAMEDICAL DEVICE Via CiscoWebex EJ Elizabeth Jose CIT PK McS C&I Smt Anup Neerja Bhata Praween Kavi Dr. Naresh Trehan Dr. Jitendra Singh Noorja Bhatia, Cli FICCI Office of the Principal Scientific Advis eb to the Government of India 25 PHILYVI COMMENCEMENT OF MANUFACTURING OPERATIONS JOINT VEN ABADPL IN ASSUT 2004 200 1997 AD Aakarghita Dutta MP Himanshu Bald, CA C Prof. K VijayRaghavan MOS C&I Smt. Anup Sanjay Bhutan Secretary Pharma Dr. Mind Kantle, Chair Investindia RAJARAMAN CHO NITAWOS Rajy Rama Devi Kannegan Shri Piyush Goval (Union Minister) DPIIT-Webinar NEXT 500 POLYMED MEDICAL DEVICES We Care As We Cure BOOK CLUB LIFE'S O AMAZING SECRETS SHI KHIMA ACHIEVE MORE Atomic Habits James Cloor Who Moned My Cheese? TRAPPORT DAD P+LMED a AGENDA AUDITORIUM EXHETION NETWORKING LOUNGE PARTNERS SPEAKERS PARTNER BOOKLET LOGOUT RICH audible Audiobook Library ASIA 2021 HEALTH ASIA HEALTH 2021 28-29 EAT THAT FROGI HARITS OF HIGHLY EFFECTIVE PEOPLE Stephen R. Cavey Books released in last Financial Year Learning is just a click away.! zoom www.polymedicure.com CM A Global Medical Technology Company 9 Manufacturing Facilities, across 4 Countries 120+ Courtes presence 1 Billion edical Devicas manufacturing cap Largest Ex airtel BLUE STAR BUILT ON TRUST POLYMED MEDICAL DEVICES We Care As We Cure 2 PHLYVED PRINCIPAL CO-PARTNERS DCM SHRIRAM Growing with trust DP WORLD P+LYMED CavinKate My Lime Her CK BIRLA CROUP EXIDE 0 Meta nbc KANC SOMANY VOLVO CI Annual Summit 2022 Confidential | Slide 29#30POLYMED MEDICAL We Care As We Cure DEVICES Corporate Communication Media | Industry Events I Webinars | Social Media I Clinical Engagements I Conferences Arab Health ARAB HEALTH 2023, Dubai P+LYMED Plan Health ☑MEDICA 2022, Germany POLYMED HEDICA DEVICES We Care As We Cure POLYMER We Care As W Plan Health A Pely Medure ip Company P+UVED VED INS Annual Conference 2022, Delhi P+LYMED P+LYMED INS P+LMED P+LMED P+LMED world of he P+LYV INFUSION NURSES SOCIETY - INDIA NS Annual Cference 2022 काकरण ATIO www.polymedicure.com ISNCON 2022, Pune POLYMED MEDICAL DEVICES 1700 S NOVATE GUAT 25 CILA CAR PDMED Confidential | Slide 30#31www.polymedicure.com POLYMED MEDICAL DEVICES We Care As We Cure Thank You Poly Medicure Limited Registered Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel: 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: [email protected] Visit: www.polymedicure.com Confidential | Slide 31

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Q4 & FY22 - Investor Presentation image

Q4 & FY22 - Investor Presentation

Financial Services

FY23 Results - Investor Presentation image

FY23 Results - Investor Presentation

Financial Services

Ferocious - Plant Growth Optimizer image

Ferocious - Plant Growth Optimizer

Agriculture

Market Outlook and Operational Insights image

Market Outlook and Operational Insights

Metals and Mining

2023 Investor Presentation image

2023 Investor Presentation

Financial

Leveraging EdTech Across 3 Verticals image

Leveraging EdTech Across 3 Verticals

Technology

Axis 2.0 Digital Banking image

Axis 2.0 Digital Banking

Sustainability & Digital Solutions

Capital One’s acquisition of Discover image

Capital One’s acquisition of Discover

Mergers and Acquisitions